Janus Henderson Global Life Sciences Fund(IE0002141913)
- Equities
- Healthcare
- Global
- USD Cash
- Accumulating
The Fund invests in companies addressing unmet medical needs or improving health care efficiencies by understanding the science and business of health care.
Invests in a well-diversified global portfolio balanced across Core, Emerging, and Opportunistic healthcare sub-sectors. Targets long-term capital growth by identifying innovative companies across the entire life sciences spectrum, including biotechnology, pharmaceuticals, and medical devices. Offers an established institutional track record, having been managed through various market cycles since its inception in 2000.
Led by an experienced Portfolio Manager with 25 years of investment experience and a foundational background in biochemical sciences. Supported by a specialized team of seven dedicated healthcare analysts, including three PhDs in science-related fields. The investment team remained stable with no changes reported during the 2024 calendar year.
Aims to deliver superior long-term total returns compared to healthcare sector peers. Designed to capture structural growth within the life sciences sector while maintaining a diversified risk profile across different healthcare industries. Performance may exhibit short-term volatility relative to broad benchmarks due to a strategic focus on innovative, smaller-sized biotechnology companies.
Utilizes a bottom-up fundamental approach to identify long-term winners across a portfolio typically comprising 80 to 120 names. Integrates sector-specific ESG considerations, such as drug pricing, waste management, and carbon emissions, and is classified as an Article 8 fund under SFDR. Includes selective allocations to private companies, providing exposure to high-growth innovators before they reach public equity markets.
Access to institutional share class with no trailer fees to achieve the lowest possible fees
It serves as a specialized satellite allocation for investors seeking targeted exposure to global healthcare and life sciences innovation. The fund's structural underweight to mega-cap pharmaceuticals and overweight to biotechnology offers a differentiated return profile compared to traditional healthcare indices. It is suitable for long-term investors who can tolerate sector-specific volatility in exchange for potential outperformance driven by medical and technological breakthroughs.
Daily data. Returns as of 16 Sep 2026.
| Year | Total | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
| 2026 | - | 0.7% | 2.0% | -6.6% | 1.8% | 2.1% | 8.2% | -0.5% | 3.7% | - | - | - | - |
| 2025 | 23.7% | 5.9% | -0.3% | -4.6% | -0.3% | -5.8% | 2.3% | -0.9% | 6.1% | 2.6% | 8.7% | 9.3% | -0.2% |
| 2024 | 2.6% | 2.7% | 3.8% | 1.6% | -4.7% | 3.5% | 3.1% | 2.6% | 5.1% | -2.5% | -3.4% | -0.7% | -7.6% |
| 2023 | 6.3% | 0.4% | -4.4% | 2.5% | 4.0% | -2.4% | 3.0% | 1.0% | -1.5% | -3.9% | -6.4% | 7.3% | 7.5% |
| 2022 | -3.6% | -8.9% | 0.5% | 3.5% | -6.9% | -1.0% | -0.9% | 3.6% | -2.6% | -3.0% | 8.4% | 5.9% | -0.9% |
| Load more | 5 of 27 | ||||||||||||
| Eli Lilly and Co | 9.69% |
| Johnson & Johnson | 6.77% |
| UnitedHealth Group Inc | 4.21% |
| AstraZeneca PLC | 4.19% |
| AbbVie Inc | 3.94% |
| Revolution Medicines Inc Ordinary Shares | 3.14% |
| Novartis AG ADR | 2.68% |
| argenx SE ADR | 2.61% |
| Praxis Precision Medicines Inc Ordinary Shares | 2.43% |
| Thermo Fisher Scientific Inc | 2.42% |
| Intuitive Surgical Inc | 2.18% |
| BridgeBio Pharma Inc | 1.91% |
| Abbott Laboratories | 1.91% |
| Vertex Pharmaceuticals Inc | 1.89% |
| Merck & Co Inc | 1.84% |
Disclaimer: ©2025 Morningstar. All Rights Reserved. The information contained here relating to a particular collective investment scheme: (1) is proprietary to Morningstar Research Pte. Limited and/or its content providers (“Information Provider(s)“) unless otherwise specified; and (2) may not be copied or distributed. Neither the Information Provider nor Endowus guarantee or endorse the accuracy, reliability, completeness or timeliness of the information, or are responsible for any damages or losses arising from any use of this information. Further, for technical reasons, certain information provided by Information Provider may be different from that supplied by the respective fund houses.
This website is for information purposes only and is not and should not be construed as an offer or the solicitation of an offer or a recommendation for the purchase or sale of any investment or subscribe for, or to participate in, any services. Any opinion or estimate above is made on a general basis and none of Endowus, nor any of its affiliates, representatives, or agents have given any consideration to nor have made any investigation of the objective, financial situation, or particular need of any user, reader, any specific person or group of persons. Opinions expressed herein are subject to change without notice. You should carefully consider whether any investment views and investment products/services are appropriate in view of your investment experience, objectives, financial resources and relevant circumstances or seek financial advice via Endowus' platform.
Investment involves risk. The value of investments and the income from them can go down as well as up, and you may not get the full amount you invested. Past performance is not an indicator nor a guarantee of future performance. Rates of exchange may cause the value of investments to go up or down. Individual stock performance does not represent the return of a fund.
You are responsible for downloads from this website. Endowus does not warrant that any downloads from this website will meet your needs or expectations, or be uninterrupted, secure, or error free or that any files available for downloading through this website are free of computer viruses or other harmful components. You alone are responsible for ensuring adequate protection and backup of data, software, computer, and other equipment is made and appropriate safeguard is in place to detect, prevent and eliminate computer viruses and other harmful effects. Neither Endowus nor the Information Provider will be responsible for any costs or expenses which may be incurred if your use of this website or if any downloads results in any servicing or replacement of property, material, equipment, or data.
This advertisement has not been reviewed by the Monetary Authority of Singapore.